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Shigella toxin is a multimeric protein consisting of one A subunit (M,., 32,000) 
and five B subunits (Mr, 6,500) (1). It is produced by all species of the genus and 
is believed to play an  important role  in pathogenesis of clinical shigellosis (2). 
Shigella  toxin  is  particularly  interesting  because  several  different  biological 
effects are mediated by the same highly purified molecule (1,  3).  For example, 
it  causes  fluid  secretion  when  placed  in  the  lumen  of rabbit  small  intestine 
(enterotoxicity)  (2),  but  results  in  delayed  limb  paralysis  and  then  death  if 
administered parenterally in the same species (neurotoxicity) (4). When directly 
injected into the vagus nerve trunk of rats, shigella toxin travels in retrograde 
fashion  via  the  axon  to  the  neuronal  cell  body,  causing  dissolution  of Nissl 
substance and death of the neuron (neuronotoxicity) (5). It is also lethal to certain 
cell culture lines (cytotoxicity) due to inhibition of protein synthesis (6,  7).  The 
latter effect has also been  shown in cell-free protein synthesis systems (8).  The 
mechanism appears  to be an irreversible and probably catalytic inactivation of 
the 60 S ribosomal subunit by the toxin A subunit (9). 
It is not known how shigella toxin produces these various manifestations. It is 
possible that there are distinctive binding sites on different tissues for the toxin 
B subunit that result in diverse effects and that the B subunit has multiple binding 
domains  that  recognize  these  distinctive receptors.  It  is  also  conceivable  that 
direct  binding of the A  subunit could cause some of the observed  effects.  In 
HeEa cells, the cytotoxic effect of shigella toxin appears to be related to binding 
of the  B  subunit to an N-linked glycoprotein on the cell surface that contains 
oligomeric ~31---~4 linked N-acetyl-D-glucosamine (GIcNAc) I.  The  evidence  for 
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this statement includes:  (a) the  loss of sensitivity to toxin when  HeLa cells are 
treated  with  tunicamycin  (10),  an  inhibitor of N-linked  glycoprotein synthesis; 
(b) competitive inhibition of the cytotoxic response of HeLa cells when incubated 
with  GlcNAc-specific lectins (10,  11) or oligomeric/31---~4-1inked GIcNAc (11); 
(c) inhibition of toxin binding and bioactivity in HeLa cells by B subunit-specific 
antibodies but not by A subunit-specific antibodies (1); and (d) the demonstration 
that renatured, purified B  subunits bind to the HeLa cell surface and compete 
for  binding  of the  holotoxin,  whereas  purified  A  subunit  neither  binds  nor 
inhibits  binding  of  the  intact  toxin  (Donohue-Rolfe,  A.,  and  G.  T.  Keusch, 
manuscript in preparation). 
Overnight incubation of cells in the presence of tunicamycin, which completely 
inhibits the cytotoxic response to  100  50%  tissue culture lethal doses (TCs0) of 
toxin, reduces toxin binding by only 55-60% (10). We have therefore suggested 
that a second toxin-binding site is present on HeLa cells and that this site is not 
involved in the cytotoxic response (10). This is the probable explanation for our 
previous observations (2) and those of Eiklid and Olsnes (7) that the response of 
HeLa cell lines of widely differing sensitivity to toxin fails to correlate with the 
number of receptors present.  Preliminary experiments have indicated that this 
second  HeLa  cell  receptor  is  a  glycolipid,  similar  to  a  chloroform/methanol 
soluble toxin-binding site on rabbit jejunal brush border membranes (2, 12). The 
present  study was  undertaken  to isolate and  identify this glycolipid from both 
HeLa cells and rabbit intestinal epithelial cells. 
Materials and  Methods 
Materials.  Casamino acids were obtained from Difco Laboratories Inc., Detroit, MI. 
Blue Sepharose CL-6B, polybuffer exchanger 94 and polybuffer 96, and DEAE-Sephadex 
were purchased  from Pharmacia  Fine Chemicals,  Piscataway,  NJ.  BioGel P-60 was ob- 
tained  from  Bio-Rad  Laboratories,  Richmond,  CA.  Chloramine  T,  Na  metabisulfite, 
rabbit hemoglobin, and BSA were from Sigma Chemical Co., St. Louis, MO. NaJ25I (17.4 
Ci/mg) and Bolton Hunter reagent were purchased from New England Nuclear, Boston, 
MA.  All tissue  culture media were from Gibco Laboratories, Grand Island,  NY.  High- 
performance thin-layer chromatography (HPTLC) plates  were  purchased  from  either 
Merck,  Darmstadt,  West Germany, or J.T.  Baker Chemical Co.,  Phillipsburg,  NJ.  Pri- 
muline was obtained from Aldrich Chemical Co., Milwaukee, WI. Soluble Gal~l---~4Gal 
was purchased from Socker-Bolaget Fine Chemicals, Arlov, Sweden. 
Toxin Production.  Shigella toxin was produced and purified in three steps from Shigella 
dysenteriae 1, strain 60 R, as previously described (1). The pure toxin was lyophilized in 
ammonium bicarbonate and stored at -70°C. The A and B subunits were dissociated in 
5% formic acid and isolated by chromatography on BioGel P-60, as previously reported 
(1).  Toxin or isolated A or B subunits were labeled with  Jz5I by a  modification of the 
chloramine T  procedure (1). 
Antibodies.  Rabbit polyclonal (Rab) and mouse monoclonal A and B subunit-specific 
antibodies (designated 5B2 and 4D3, respectively) have been described before (I).  Rat 
lgM  mAb  to  Gb~  (globotriaosylceramide)  2 and  an  IgG~  mouse  mAb  raised  against 
Ill :~ FucnLc4, designated 38.13 and FH3, respectively, were prepared and characterized 
as previously reported (13,  14). For some experiments, these antibodies were iodinated 
by the Bolton Hunter method (15). 
Growth of HeLa Cells and Assay of Shigella Cytotoxicity.  HeLa cells (CCL-2; American 
Type Culture Collection, Rockville, MD) were grown at 37°C in McCoys 5a (modified) 
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of the International Union of Pure and Applied Chemistry. JACEWICZ  ET  AL.  1393 
medium containing  I0%  FCS (16).  50 ml of packed HeLa ceils were obtained for lipid 
studies  after  passaging cells  to  multiple  150-ram  Petri  dishes.  Cells  were  harvested  by 
scraping with  a  rubber  policeman,  centrifuged at  low speed,  and  the  pellet  was frozen 
until  used.  Toxin  was assayed with  a  previously described  cytolethal  assay using  tteLa 
cells in rnonolayer culture in microtiter plates (16). 
Extraction and Purification of Lipids.  The total lipid was extracted from packed HeLa 
cells or rabbit jejunal mucosal scrapings in isopropanol/hexane/water (55:25:20) and dried 
in a  rotary evaporator (17).  A  Folch partition  was performed  in  chloroform/methanol 
(2:1)  (18).  The  upper  phase  gtycolipids  were  then  fractionated  by  DEAE-Sephadex 
chromatography to obtain the upper neutral (UN) glycolipids, while leaving gangliosides 
still bound to the column (19). The lower phase (LP) glycolipids from the Folch partition 
were  acetylated,  purified  on  a  Florisil  column,  and  deacetylated  (20).  Authentic  Gb3 
standard  was  purified  from  human  erythrocyte  membranes  by  HPLC,  as  previously 
described  (21).  IsoGb3 was  prepared  from  rat  globoisotetraosylceramide  by enzymatic 
hydrolysis with/3-galactosidase (22). 
High-Performance Thin-Layer Chromatography.  Gb3 was purified  from  LP glycolipids 
from  HeLa  cells  and  rabbit jejunal  mucosa by preparative  HPTLC,  as  previously de- 
scribed,  using the solvent system chloroform/methanol/water (60:35:7) and detected by 
staining with primuline (13). The upper (U) and lower (L) bands of the Gb3 doublet were 
separated, isolated for use in some studies, and designated Gb3-U and Gb3-L, respectively. 
The specificity of the toxin was tested by direct binding studies to glycolipids separated 
on HPTLC SI plates (J.T. Baker Chemical Co.) in chloroform/methanol/water (50:40:10) 
containing 0.02% CaCI., (final concentration). Dried plates were soaked for 1 min in 0.5% 
polyisobutylmethacrylate in acetone, dried, sprayed with 5% BSA in PBS, and then soaked 
in  the same solution  for 2  h  (13).  Finally,  the plates  were incubated at  4°C for 4  h  in 
PBS/0.1% BSA containing 2 x  105 cpm/ml of 12~I-toxin (sp act ~5 X 104 cpm/ng), washed 
thoroughly, dried, and autoradiograms were prepared (XAR-5 film, Eastman Kodak Co., 
Rochester,  NY).  To  visualize  the  separated  glycolipids, plates  were  then  sprayed  with 
0.5% orcinol in  10% aqueous HeSO4 and heated to 100°C. 
Solid Phase Binding Studies.  Five parts of lecithin and three parts of cholesterol were 
mixed  with  one  part  (w/w)  of purified  glycolipid  in  absolute  ethanol  to  achieve  a 
concentration of 4  mg glycolipid per ml.  Glycolipids used  included  LacCer,  iGb3,  Gb~, 
Gb4, nLc6, and Gg4. 50 #1 of this mixture was added to the first well and serial twofold 
dilutions were made with absolute ethanol in 96-well, soft fiat-bottomed microtiter plates. 
The plates were dried at 37°C for  1 h and then incubated with PBS/5% BSA for 2 h  to 
block nonspecific binding sites. Blocking solution was then replaced with either iodinated 
toxin or purified A or B subunits in 30 ml of PBS/0.1%  BSA for 4 h at 4°C. Wells were 
washed five times with PBS, cut with a hot wire, and radioactivity was counted in a gamma 
spectrometer. 
In  some  experiments,  liposomes  were  prepared  by  sonication  of  the  same  leci- 
thin/cholesterol/glycolipid  mixtures in  PBS.  HeLa cells were grown to near confluency 
in quadruplicate tissue culture microtiter plates and then incubted with 5% BSA in PBS 
for  1 h.  Plates were chilled to 4°C and serial  dilutions of the  liposomes were added so 
that the first well contained 500 ng of glycolipid. Control plates were identically prepared 
except for the omission of liposomes. J2r'I-toxin (105 cpm) was then added.  After 2 h of 
incubation with shaking at 4°C, all plates were washed five times in PBS. One set of plates 
was used to measure bound radioactivity in a gamma scintillation counter. The second set 
of plates was inoculated with 200 #1 of fresh McCoy's medium per well, incubated at 37 °C 
overnight, and cytotoxicity was measured as described above. 
Results 
HPTLC of HeLa  Cell and  Rabbit Jejunal  Lipids  and  Toxin  Binding.  Fig.  1A 
shows the orcinol  staining  pattern  of isolated  UN and  LP lipids  obtained  from 
HeLa  cells  and  rabbit  jejunum,  and  standards  separated  by  HPTLC.  The 
autoradiogram  obtained  after  incubation  of this  plate  with  iodinated  toxin  is 1394  GLYCOLIPID  RECEPTOR  FOR  SHIGELLA  TOXIN 
FIGURE  1.  H PTLC separation of glycolipid  preparations. Lane l, UN glycolipid  fraction of 
group B human erythrocytes; lane 2, UN glycolipid  fraction of HeLa cells; lane 3, LP fraction 
of HeLa cells; lane 4, UN glycolipid fraction of rabbit jejunum; lane 5, LP fraction of rabbit 
jejunum;  lane 6,  LacCer standard; lane 7, Gbs standard; lane 8, UN glycolipid fraction of 
group  A  human  erythrocytes.  The  plate  was  developed  in  chloroform/methanol/water 
(50:40:10). (A) HPTLC plate stained by orcinol/H2SO4 reaction. (B) autoradiogram  after 
incubating plate with 125I-shigella  toxin. Markers, the known mobility of various glycolipids. 
shown in Fig.  lB. Toxin bound strongly to authentic Gb3 and to Gb3 present in 
UN  and  LP glycolipid preparations  from both  HeLa cells and  rabbit jejunum, 
and from human type A and type B erythrocytes. Toxin also bound to a doublet 
band migrating in the position where Gb4 is found. In addition, a  labeled band 
was detected in type B erythrocyte glycolipids, migrating between B1 and H~  in 
the expected position of P~ antigen. Overnight incubation of cells in the presence 
of 0.05 #g/ml of tunicamycin before extraction of the glycolipid fraction failed 
to diminish toxin binding to HeLa Gb~ on HPTLC plates (data not shown). 
Solid-Phase Binding  Studies.  Fig.  2  shows  the binding of 125I-toxin to glyco- 
lipid-coated microtiter plates.  Toxin bound  to purified erythrocyte Gb3 and to 
the  isolated  upper  and  lower  bands  of the  Gb~  doublet  (Gb3-U  and  Gb3-L, 
respectively) in both HeLa cell and rabbit jejunal  LP glycolipids. The extent of 
binding to Gb3-U and  Gb~-L lipids from each  tissue was similar,  and  was  -50- 
fold greater to Gb~ than to LacCer, as estimated from the titration curve shown 
in Fig.  2. There was no detectable binding to iGb3, Gb4, nLc4, or nLc6. 
Consistent  results  were  observed when  glycolipid-containing liposomes  were 
used  to  compete  for  toxin  binding  to  HeLa  cell  monolayers  (Fig.  3).  Thus, 
purified Gb3 was a highly effective inhibitor, whether obtained from erythrocyte 
membranes  or  from  HeLa cells or  rabbit jejunum.  Isolated  Gb3-U  and  Gb3-L 
front  HeLa and  rabbit  LP glycolipid extracts were  similar  in  ability  to  inhibit 
binding of toxin to HeLa cell monolayers. Liposomes containing LacCer, nLc6, 
or  IVZFucnLc4 were inactive in these experiments.  In addition,  neither soluble 
cbitotriose (1  mg/ml) nor soluble Gai~l--*4Gal (1  mg/ml), the terminal disaccha- 
ride of Gb3, inhibited toxin binding (data not shown). 
The effect of anti-glycolipid and anti-toxin antibodies on toxin binding to Gb3 
from the different tissues was then studied (Fig. 4). In contrast to antibody FH3, 
which was raised against an unrelated glycolipid antigen and had no discernible 80 
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FIGURE  2.  Solid-phase  binding of  ~SI-shigella  toxin  to  glycolipids.  Lecithin/cholesterol/ 
glycolipid mixtures (5:3:1) were prepared and serial dilutions were coated on microtiter plates 
so that the first well contained 200 ng of glycolipid.  Wells were blocked with PBS/5%  BSA 
and  1 ng of iodinated toxin was added for 4 h at 4°C. Plates were washed thoroughly and 
radioactivity was determined. ©, Gb3 standard; Q, LacCer; A, Gb3-U; A, Gb3-L; Fq, mixture of 
iGb~, Gb4, nLc4, and nLc6. 
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FIGURE 3.  Liposomes  were  prepared  by  sonicating  a  5:3:1 mixture  in  PBS  of  leci- 
thin/cholesterol/glycolipid. Beginning with  a  concentration of 500  ng of glycolipid,  serial 
dilutions of liposomes were added to HeLa cell monolayers in microtiter plates that had been 
previously incubated with PBS/5%  BSA for 1 h at 4°C.  1 ng of 12~I-toxin was added to each 
well and incubated at 4°C for 2 more h. Plates were thoroughly washed and radioactivity was 
determined. Inhibition of binding in the presence of the different glycoprotein-containing 
liposomes was calculated  by comparison  with  identically  treated  control wells containing no 
liposomes.  Duplicate plates  were  used for the cytotoxicity data  shown  in Table  I. ©,  Gb3 
standard; O, LacCer; A, Gb~-U; •, Gb3-L;  F-l, nLc6;  I, IV FucnLc4. 
effect (O), antibody 38.13 directed to Gb~ resulted in a small but definite decrease 
in toxin binding, best seen with rabbit Gb3-U  and  HeLa Gb3-L (O).  In contrast, 
both Rab, rabbit polyclonal antitoxin (A), and 4D3, mouse monoclonal B subunit- 
specific antibody (A),  virtually eliminated toxin  binding at a  titer of  1:1,000.  It 
should be  noted  that  the  initial concentration  of these  two  antibodies  was  10- 
fold less than either FH3 or 38.13. The weak inhibitory effect of 38.13 antibody 1396  GI,YCOL1P1D RECEPTOR FOR  SHIGELLA TOXIN 
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FIGURE 4.  Inhibition of toxin binding to glycolipid-coated microtiter plates in the presence 
of antibody. Plates were coated with a mixture of lecithin/cholesterol/glycolipid (5:3:1) so that 
each well contained  100 ng of glycolipid, and then were blocked with PBS/5%  BSA. Serial 
dilutions of antibodies were added to the wells so that the initial dilution of 38.13 and FH3 
was 1:100 and the dilution of Rab and 4D3 was l : 1,000 in the first welt. Plates were incubated 
with  12'~I-toxin and binding determined as described. O,  plates treated with antibody 38.13 
(anti-Gbs); O,  plates  treated  with  antibody  FH3  (anti-llI3FucnLc4);  A,  plates  treated  with 
antibody Rab; and A, plates treated with 4D3 (mouse monoclonal anti-B subunit). 
is  probably  related  to  its  inability to bind  strongly to Gb3-coated plates,  since 
only 0.5%  of the  input counts of 125I-labeled  antibody were  observed  to bind 
(data not shown). 
Binding of Isolated A and B Subunits to Gb~.  Fig. 5 shows the binding of toxin 
subunits to glycoprotein-coated microtiter plates.  ~z'~I-B subunit bound to Gh3 
(A)  but  not  to  LacCer  (&),  whereas  the  A  subunit  failed  to  bind  to  either 
glycolipid (O e).  Fig.  6  shows competitive inhibition of binding of intact  ]zsI- 
toxin to Gb~ by unlabeled shigella toxin or isolated A and B subunits. Both intact 
toxin (I--1) and B subunit (A) were good competitive inhibitors, whereas A subunit 
(©) or cholera toxin (m) were not. JACEWICZ  ET  AL.  1397 
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FIGURE 5.  Binding of ]251-toxin subunits to microtiter plates coated with either Gbs (open 
symbols) or LacCer (closed symbols). Incubation was for 4 h at 37°C. 
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FIGURE 6.  Inhibition of binding of  ]251-shigella  toxin  to  Ob~-coated  microtiter plates  by 
unlabeled shigella toxin (V'l) or isolated A  or B subunits (© and/x, respectively) and cholera 
toxin (I).  The initial concentration of the competing molecule represents a  100-fold molar 
excess in relation to iodinated holotoxin. 1398  GLYCOLIPID  RECEPTOR  FOR  SHIGELLA  TOXIN 
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FIGURE  7.  Effect  of subunit-specific antibodies  4D3  (B  subunit-specific, @) and  5B2  (A 
subunit-specific, O) on binding of ~251-1abeled holotoxin (A), A subunit (B), or B subunit (C) to 
Gbs-coated microtiter plates. Beginning with a dilution of antibody of 1:1,000 in the first well, 
serial  dilutions  were  made and  5  x  105  cpm  of toxin  or  subunit  were added.  Incubation 
proceeded for 4 h at 4°C. 
Additional  experiments  were  then  performed  to  determine  the  effect  of 
subunit-specific antibodies on  the binding of intact toxin or isolated A  and  B 
subunits to Gba-coated microtiter plates (Fig. 7). The binding of holotoxin and 
B subunit (Fig. 7, A and C, respectively) was inhibited by the B subunit-specific 
antibody,  4D3  (@), but  not  by  the  A  subunit-specific antibody,  5B2  (O).  In 
contrast, the limited binding of the A subunit (panel B) was inhibited by the A- 
specific antibody but not by the B-specific antibody (note the 10-fold decrease in 
scale of the ordinate). These data show that the binding of the A subunit to Gb3 
was not due to contamination of the A subunit preparation by the B subunit. 
Competitive Inhibition of the Cytotoxic Response of HeLa Cells to Shigella Toxin by 
Glycolipid-Containing Liposomes and Soluble Oligosaccharides.  In parallel with the 
competitive binding studies shown in Fig. 3, the cytotoxic response of HeLa cells 
was determined in the presence of serial dilutions of glycolipid-containing iipo- 
somes (Table I).  Neither Gb.s (whether obtained from erythrocytes, HeLa cells, 
or rabbit jejunum) nor non-toxin-binding glycolipids inhibited cytotoxicity, al- 
though all Gb3 liposomes inhibited binding of toxin to HeLa cells by >90% (Fig. 
3).  The soluble terminal Gal~l-*4Gal disaccharide of Gb3 also failed to affect 
toxin activity in HeLa monolayers, whereas chitotriose had a marked inhibitory 
effect (Table II). JACEWICZ  ET  AL. 
TABLE  I 
Effect of Glycolipids Incorporated  into Liposomes on the Cytotoxic 
Response of HeLa Cells to Shigella  Toxin 
Glycolipid present in  Percent HeLa cell mortality 
liposomes  Control (no toxin)  Toxin 
None  0.0  46.0 
nLc6  0.3  46.4 
IV  2 FucnLc4  0.8  46.4 
HeLa LacCer  0.3  46.4 
HeLa GbrU  0.1  47.1 
HeLa Gb3-L  0.0  46.4 
Rabbit Gbs-U  0.1  46.8 
Rabbit Gb3-L  0.8  47. I 
Erythrocyte Gb~  0.1  45.9 
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TABLE  II 
Effect of Oligosaccharide Hapten Inhibitors  on the Cytotoxic Response 
of HeLa Cells to Shigella Toxin 
Oligosaccharide 
added 
Percent HeLa cell mortality 
Toxin +  Chitotriose  Toxin +  Gal-Gal 
mg/ml 
0.0  57.3  58.2 
1.0  27.0  58.4 
0.5  30.5  57.0 
0.25  33.6  57.0 
0.125  35.9  57.5 
Discussion 
In  this  paper  we  have  shown  that  shigella  toxin  can  specifically bind  to  a 
glycolipid present in both rabbit jejunal mucosa and HeLa cells. This glycolipid 
was identified as Gb3 (giobotriaosylceramide) by comparison  of its mobility on 
HPTLC  with  that  of authentic  Gb3  isolated  from  human  type  B  erythrocyte 
membranes.  Rabbit jejunal  or  HeLa cell  Gb3 and  purified  Gb3 derived  from 
human type B erythrocytes all showed similar toxin binding capacity. Moreover, 
when  these  sources  of Gb3  were  incorporated  into  liposomes  they  possessed 
similar ability to competitively inhibit the binding of toxin to HeLa monolayers. 
Toxin  also  bound  to  a  second  band  in  the  glyco|ipid  extracts  of erythrocyte 
membranes  in  the  position  at  which  Gb4  and  aOH-Gb~  (Gb3  containing  ~- 
hydroxylated fatty acid and  phytosphingosine)  are  known  to comigrate.  Since 
toxin was unable to bind to purified Gb4 in solid phase binding studies it is likely 
that  the  minor  band  detected  is  aOH-Gb3.  A  third  toxin-binding  band  was 
identified in type B human erythrocyte extracts, which is probably the proposed 
P~ erythrocyte antigen structure,  IVaGalnLc4 (23). This has a Gal o~1---~4 linked 
to riLE4 so that it possesses the same terminal Galal---*4Gal disaccharide structure 
as Gb3,  but linked  /31---~4 to GicNac instead  of Glc.  As this  glycolipid was not 
available for further study, experiments to confirm this interpretation  were not 
possible. The  important  observation,  however,  is the  identification  of the  Gb3 1400  GLYCOLIP1D  RECEPTOR  FOR  SHIGELLA  TOXIN 
glycolipid-binding site for shigella toxin in rabbit jejunum and HeLa cells. This 
is consistent with preliminary studies of other investigators, who have reported 
that the specific disaccharide, Galc~l---->4Gal coupled to BSA, inhibits the binding 
of shigella toxin to HeLa cells (24). 
Our data show the fine specificity of the binding for Gb3, since neither iGb3 
(which is identical to Gb3 except that the Gal-Gal disaccharide is linked c~1---~3 
instead of al---~4) nor  LacCer (which  differs from Gb~  in  the deletion of the 
terminal galactose residue) or Gb4 (which has a terminal GalNAc linked/31-->3 
to  Gb3) were able  to bind  shigella toxin.  Since soluble  Galal--->4Gal  failed to 
competitively inhibit binding of toxin to HeLa cells, our evidence indicates that 
receptor  activity for  shigella  toxin  requires  terminal  Galo~l---~4Gal linked  to 
another residue (either Glc or GIcNAc from the studies described here).  It is 
also clear that the binding of toxin to Gb~ is via the toxin B subunit. Purified B 
subunit bound to Gb:~ but not to LacCer, whereas purified A subunit bound to 
neither glycolipid. This is consistent with our observation that only the holotoxin 
or the B subunit, but not the A subunit or cholera toxin, inhibited binding of 
intact ~z'~I-holotoxin to Gb3-coated microtiter plates. A third piece of evidence is 
that  binding of toxin  or  B  subunit  to  Gbs  was  completely inhibited  by  a  B 
subunit-specific mAb, whereas an A subunit-specific mAb had no effect. 
The Gb3 toxin-binding component was detected in HeLa cells.  Moreover, the 
binding of shigella toxin to these cells  was  competitively reduced by >90%  in 
the presence  of Gb3  incorporated  into  liposomes.  Nevertheless,  we  found no 
evidence that binding to Gb3 was responsible for the HeLa cell  cytotoxicity of 
shigella toxin, since the addition of Gb3-containing liposomes failed to diminish 
the cytotoxic response of HeLa monolayers to toxin. This is not entirely surpris- 
ing because we have previously presented evidence that cytotoxicity is mediated 
by  a  tunicamycin-sensitive glycoprotein  containing  GlcNAc  linked  /31---4 to 
GlcNAc (10).  The  present  studies provide additional data  to  support  this,  as 
shown by the competitive inhibition of toxicity by trimeric/31---~4-1inked  GlcNAc 
(chitotriose). We have also found that overnight incubation of HeLa cells in the 
presence of a sufficient concentration of tunicamycin to completely abrogate the 
response to  100  TC~0 doses of toxin, reduces specific binding of toxin by only 
55-60%  (10),  and does not appear to diminish the amount of the extractable 
glycolipid toxin-binding component of HeLa cells (present study). This residual 
binding can now be explained, at least in part, by the tunicamycin-resistant Gb:~ 
receptor. That this is distinct from a glycoprotein cytotoxic receptor is also shown 
by the  observation  that chitotriose inhibited the toxicity of shigella toxin  for 
HeLa cells but not its binding to Gb3-coated microtiter plates. It is most interest- 
ing to note that while toxin binding to both receptors appears to be via the same 
toxin  B  subunit,  as  indicated  by  studies  with  purified  subunits  and  subunit- 
specific mAbs,  the glycoprotein and glycolipid binding sites exhibit distinctive 
sugar  specificities  (GIcNAc/31---->4GIcNAc-  and  Galc~l---~4Gai/31---~4 Glc  or 
GlcNAc, respectively). We do not at present know how many different functional 
domains are  present  on  the M,.  6,500  B  subunit peptide,  nor  whether the  B 
subunit-specific monoclonal, 4D3, recognizes more than one domain. We believe 
a more likely hypothesis is that 4D3  directly binds to one binding domain and 
sterically inhibits, but does not bind to, a  second domain. Thus we propose a JACEWICZ  ET  AL.  1401 
novel mechanism to explain the diverse effects of toxin that involves two distinct 
sugar-specific binding sites on the same small peptide that mediate the different 
biological activities.  More data are certainly needed to reach a  firm conclusion 
about this. 
Rabbit jejunum  responds  in  vivo  to  binding  of toxin  to  the  brush  border 
surface by net secretion of isotonic fluid, but in contrast to the HeLa cell does 
not exhibit any histologically demonstrable cytotoxic response (25).  Preliminary 
studies with purified rabbit jejunal microvillus membranes (MVM) have shown a 
single class of binding site for toxin (26, 27), and the present study indicates that 
this is Gb:~. Since Gb3 apparently does not mediate  toxin effects in  HeLa cells, 
the  obvious question  is  whether  or  not  binding  to  gut  Gb3 initiates  the  fluid 
secretory  response  of rabbit  small  bowel.  We  cannot  completely  answer  this 
question  now,  but  other  preliminary  observations  from  our  laboratory  are 
consistent  with  such a  role.  We  have  reported  that  the  appearance  of Gb~  in 
rabbit jejunum  is developmentally regulated  in  the  New Zealand white  rabbit 
(12). Thus, animals younger than  16 d  (and responsive to cholera toxin) do not 
secrete  fluid  when  shigella  toxin  is  placed  in  ligated  small  bowel  loops  (27). 
However, a consistently positive fluid response occurs in animals older than  18 
d  when  Gb~  becomes detectable in jejunal  MVM, and  binding  of 125I-toxin  to 
MVM is also demonstrable.  While these results do not prove the physiological 
relevance of the Gb3 receptor, the data certainly suggest that binding to Gb3 in 
rabbit gut is coupled to a  fluid secretory process. We presume that  we cannot 
show any effect of toxin  binding  to HeLa cell Gb3 because HeLa cells are not 
secretory cells. 
Gb:~ is also the determinant  of the pk blood group antigen (28). The Galc~l---~ 
4Gal  disaccharide  of pk,  whether  terminal  as  in  Gb3 or  internal  as  in  Gb4,  is 
recognized by the GaI-Gal pilus of uropathogenic Escherichia  coli (29-31).  This 
structure, also termed P pilus (after the P blood group system) or PAP pilus (for 
pyelonephritis-associated  pilus),  has been shown to be a  virulence determinant 
of pill-positive  E.  coli  strains,  since  it allows recognition  and  binding  to renal 
epithelial membrane glycosphingolipids containing Galcd---~4Gal  (32, 33). Prog- 
ress towards developing a  vaccine for these strains of E.  coli based on immuni- 
zation  with  Gal-Gal  pill  or synthetic  Gal-Gal  has  been  reported  (33,  34).  The 
common Gb~ receptor for shigella toxin and Gal-Gal positive uropathogenic E. 
coli suggests homology between domains of the shigella toxin B subunit and the 
Gal-Gal pilus. It is therefore possible that antitoxin antibodies might be generated 
by immunization with a Gal-Gal pilus vaccine. This might prove to be of practical 
use  if immunization  with  receptor  analogues  fails  to  significantly  block  toxin 
activity,  as already  observed with  the  anti-Gb3  mAb  used  in  these  studies.  It 
would be most interesting if a Gal-Gal pilus vaccine generated both antipilus and 
antitoxin  antibodies  to  induce  simultaneous  resistance  to  pyelonephritis  and 
shigellosis. 
Summary 
A glycolipid that specifically binds shigella toxin was isolated from both HeLa 
cells and rabbit jejunal mucosa and identified as globotriaosyiceramide (Gb~) by 
its identical mobility on HPTLC to authentic erythrocyte Gb3. Toxin also bound 1402  GLYCOLIPID  RECEPTOR  FOR  SHIGELLA  TOXIN 
to a band tentatively identified as o~-hydroxylated Gb3. In addition, toxin bound 
to  Pl  antigen  present  in  group  B  human  erythrocyte glycolipid extracts.  The 
common  feature  of the  three  binding  glycolipids  is  a  terminal  Galal---~4Gal 
disaccharide  linked/31---4  to either Glc or GIcNAc.  Globoisotriaosylceramide, 
which differs from Gb3 only in possessing a  Galo~l--*3Gal terminal disaccharide, 
and  LacCer,  which  lacks  the  terminal  Gal  residue  of Gb3,  were  incapable  of 
binding the toxin.  Binding was shown to be mediated by the B  subunit by the 
use of isolated toxin A and B subunits and monoclonal subunit-specific antibod- 
ies.  Gb3-containing  liposomes  competitively  inhibited  the  binding  of toxin  to 
HeLa cell monolayers but did not inhibit toxin-induced cytotoxicity. 
These studies show an  identical carbohydrate-specific glycolipid receptor for 
shigella toxin in gut and  in  HeLa cells.  The toxin  B subunit that mediates this 
binding has also been shown to recognize a glycoprotein receptor with different 
sugar specificity. Thus, we have demonstrated that the same small (Mr 6,500) B 
subunit polypeptide has two distinctive carbohydrate-specific binding sites. The 
Galo~l---~4Gal  disaccharide of the glycolipid toxin receptor is also recognized by 
the Gal-Gal pilus of uropathogenic E.  coli. This suggests the possibility that the 
pilus and toxin B  subunit contain homologous sequences.  If this is true, it may 
be  possible  to  use  the  purified  Gai-Gal  pilus  to  produce  toxin-neutralizing 
antibodies. 
Received  for publication 3 February 1986. 
References 
1.  Donohue-Rolfe, A.,  G. T. Keusch, C.  Edson, D. Thorley-Lawson, and M. Jacewicz. 
1982.  Pathogenesis of shigella  diarrhea.  IX.  Simplified high  yield purification of 
shigella toxin and characterization ofst,  bunit composition and function by the use of 
subunit-specific monoclonal and polyclonal antibodies. J. Exp. Med. 160:1767-1781. 
2.  Keusch, G.  T., A.  Donobue-Rolfe, and  M. Jacewicz.  1985.  Shigella toxin and the 
pathogenesis of shigellosis.  Ciba Found. Symp. 112:193-214. 
3.  Eiklid,  K.,  and  S.  Olsnes.  1983.  Animal  toxicity of Shigella dysenteriae cytotoxin: 
evidence that  the  neurotoxic, enterotoxic and  cytotoxic activities are due  to one 
toxin. J. Immunol.  130:380-384. 
4.  Keusch, G. T., A. Donohue-Rolfe, and M. Jacewicz. 1982. Shigella toxin(s):  descrip- 
tion and role in diarrhea and dysentery. Pharmacol. & Ther. 15:403-438. 
5.  Wiley,  R.  G,  A.  Donohue-Rolfe, and  G.  T.  Keusch.  1985.  Axonally transported 
shigella cytotoxin is neuronotoxic.J. Neuropathol. & Exp. Neurol. 44:496-506. 
6.  Keusch, G. T.  1973. Pathogenesis of shigella diarrhea. III. Effects of shigella  enter- 
otoxin in cell culture. Trans. N.E Acad. Sci. 35:51-58. 
7.  Eiklid, K., and S. Olsnes. 1980. Interaction of Shigella shigae cytotoxin with receptors 
on sensitive and insensitive cells. J. Receptor. Res. 1  : 199-213. 
8.  Olsnes,  S.,  and  K.  Eiklid.  1980.  Isolation  and  characterization of ShigeUa shigae 
cytotoxin.J. Biol. Chem. 256:284-289. 
9.  Reisbig, R.,  S. Olsnes, and K. Eiklid.  1981. The cytotoxic activity of shigella toxin: 
evidence  for  catalytic  inactivation  of the  60S  ribosomal  subunit. J.  Biol. Chem. 
256:8739-8744. 
10.  Keusch, G. T., M. Jacewicz, and A.  Donohue-Rolfe. 1986. Pathogenesis of shigella 
diarrhea. Evidence for an N-linked glycoprotein receptor and receptor modulation 
by fl-galactosidase.J. Infect. Dis. 153:238-248. JACEWICZ  ET  AL.  1403 
11.  Keusch,  G.  T.,  and  M.  Jacewicz.  1977.  Patbogenesis  of shigella  diarrhea.  VII. 
Evidence  for  a  cell  membrane  toxin  receptor  involving  B1--*4-1inked  N-acetyl-D- 
glucosamine oligomers.J. Exp. Med.  146:535-546. 
12.  Mobassaleh,  M.,  A.  Donohue-Rolfe,  R.  K.  Montgomery, G.  T.  Keuscb, and  R. J. 
Grand. 1985. Postnatal development of shigella toxin binding sites on rabbit intestinal 
microvillus membranes. Abstracts of the Twenty-fifth  Interscience  Conference on Antimi- 
crobial Agents and Chemotherapy.  149. 
13.  Nudelman,  E.,  R.  Kannagi,  S.  Hakomori,  M.  Parsons,  M.  Lipinski, J.  Wiels,  M. 
Fellous, and T. Tursz.  1983. A glycolipid antigen associated with Burkitt lymphoma 
defined by a monoclonal antibody. Science (Wash. DC). 220:509-511. 
14.  Fukushi,  Y.,  S.  Hakomori, E.  Nudehnan,  and  N. Cochran.  1984.  Novel fucolipids 
accumulating in human adenocarcinoma.  II. Selective isolation of hybridoma anti- 
bodies that  differentially recognize mono-, di-, and  trifucosylated type 2  chain. J. 
Biol. Chem. 259:4681-4685. 
15.  Bolton,  A.  E., and W.  M.  Hunter.  1973.  The labelling of proteins to high specific 
radioactivities  by  conjugation  to  a  l'~SI-containing  acylating  agent.  Biochem. J. 
133:529-539. 
16.  Keusch, G. T., M. Jacewicz, and S. Z. Hirschman.  ! 972. Quantitative microassay in 
cell culture for enterotoxin of Shigella  dysenteriae  1. J. Infect. Dis.  125:539-541. 
17.  Kannagi,  R.,  M.  N.  Fukuda,  and  S.  Hakomori.  1982.  A  new  glycolipid antigen 
isolated from human  erythrocyte membranes reacting with antibodies directed  to 
globo-N-tetraosylceramide (globoside).J. Biol. Chem. 257:4438-4442. 
18.  Folch, J., S. Arsove, andJ.  A. Meath.  1972.  Isolation of brain strandin. A new type 
of large molecule tissue component. J. Biol. Chem. 191:819-831. 
19.  Yu,  R.  K.,  and  R.  W.  Ledeen.  1972.  Gangliosides of human,  bovine, and  rabbit 
plasma.  J. Lipid Res.  13:680-686. 
20.  Saito, T., and S.  Hakomori.  1971.  Quantitative isolation of total glycosphingolipids 
fi'om animal cells.J. Lipid Res.  12:257-259. 
21.  Watanabe, K., and Y. Arao.  1981. A new solvent system for the separation of neutral 
glycosphingolipids. J. Lipid Res.  22:1020-1024. 
22.  Siddiqui, B.,J. Kawanami, Y. -T. Li, and S. Hakomori. 1972. Structures ofceramide 
tetrasaccharides  from various sources:  uniqueness of rat kidney ceramide tetrasac- 
charide.J. Lipid Res.  13:657-662. 
23.  Naiki,  M., J.  Fong,  R.  Ledeen, and  D.  M.  Marcus.  1975.  Structure of the human 
erythrocyte blood group P~ glycosphingolipid. Biochemistry.  14:4831-4836. 
24.  Brown,J. E., G. R. Fanning, and A. A. Lindberg. 1985. Identification ofa glycolipid 
receptor  for  Shiga  toxin  from  Shigella  dysenteriae  1.  Abstr.  Annu.  Meet.  Am.  Soc. 
Microbiol.  36. 
25.  Steinberg,  S.  E., J.  G.  Banwell, J.  H. Yardley, G. T.  Keusch, and T.  R.  Hendrix. 
1975. Comparison of secretory and histologic effects of shigella and cholera entero- 
toxins in rabbit jejunum. Gastroenterology.  68:309-317. 
26.  Fuchs, G., A.  Donohue-Rolfe, R. K. Montgomery, G. T. Keusch, and R. J. Grand. 
1984.  Evidence  of a  receptor  for  shigella  toxin  on  rabbit  intestinal  microvillus 
membranes. Gastroenterology.  86:1083. (Abstr.) 
27.  Mobassaleh,  M.,  A.  Donohue-Rolfe,  R.  K.  Montgomery,  R. J.  Grand,  and  G.  T. 
Keusch. 1986. Functional characterization of age dependent binding of shigella toxin 
to rabbit intestinal microvillus membranes. Gastroenterology.  In press. (Abstr.) 
28.  Marcus, D. M., S. K. Kundu, and A. Suzuki. 1981. The P blood group system: recent 
progress in immunochemistry and genetics. Semin.  Hematol.  18:63-71. 
29.  Vaisanen,  V., J.  Elo,  L.  Tallgren,  A.  Siitonen,  P.  Makela,  C.  Svanborg-Eden,  G. 
Kallenius, S.  B. Svenson, H. Hultberg, and T.  Korhonen.  1981.  Mannose-resistant 1404  GLYCOLIPID RECEPTOR  FOR  SHIGELLA  TOXIN 
hemagglutination and P antigen recognition characteristic of E. coli causing primary 
pyelonephritis. Lancet. 2:1366-1369. 
30.  Kallenius, G., R. Mollby, S.  B. Svenson, J. Winberg, A. Windblod, S.  Svenson, and 
B. Cedergren.  1980.  The pk antigen as receptor for the hemagglutinin of pyelone- 
phritic Escherichia  coti. FEMS (Fed. Eur. Microbiot.  Soc.) MicrobioI.  Lett.  7:297-302. 
31.  Bock, K., M.  E. Breimer, A. Brignole, G. C. Hansson, K-A. Karlsson, G. Larson, H. 
Leffler, B.  E. Samuelsson, N. Stromberg, and C.  Svanborg Eden.  1985.  Specificity 
of binding of a  strain of uropathogenic Escherichia  coli to Gal~l---~4Gal-containing 
glycosphingolipids.J. Biol.  Chem.  260:8545-8551. 
32.  Leffler, H., and C. Svanborg-Eden.  1981.  Glycolipid receptors for uropathogeneic 
Escherichia  coli on human erythrocytes and uro epithelial cells. Infect.  lmmun. 34:920- 
929. 
33.  O'Hanley,  P.,  D.  Lark,  S.  Falkow,  and  G.  Schoolnik.  1985.  Molecular  basis  of 
Escherichia  coli colonization of the upper urinary tract in BALB/c mice. J. Clin. Invest. 
75:347-360. 
34.  Schmidt,  M.  A.,  P.  O'Hanley,  and  G.  Schoolnik.  1985.  Gal-Gal  pyelonephritis 
Escherichia  coli pili linear immunogenic and antigenic epitopes.J. Exp. Med.  161:705- 
717. 